John Parkinson

The Centers for Disease Control and Prevention (CDC) is looking into the possibility of this rare group of infections emerging.

A new CDC report highlights another health-related area where interruptions occurred due to the pandemic, but data suggests both improved rapidly.

TP-05, a novel, oral therapeutic recently reported topline results from its phase 1 study.

A large health system saw a reduction of 40% and 70% respectively when the antiviral was prescribed.

A single-dose of acoziborole could simplify the treatment of this fatal infection.

A new report looked at mortality over a 2 ½ year period, and the epidemiology of who was most affected.

Postural orthostatic tachycardia syndrome (POTS) is happening in people post-virus as well as within a 90-day period post-vaccination.

The Wistar Institute’s research on DNA-encoded SARs-CoV-2 monoclonal antibodies (DMAbs) allowed it to advance to clinical trials. One researcher explains how it differs from the mRNA platform.

With an already overwhelming respiratory virus season with RSV and influenza, the hope is to prevent COVID-19 with these vaccines available to younger pediatric populations.

A clinician offers insight into what he sees in terms of these therapies and the need to get more information to those providers in the field as well as access to them.

With the proliferation of therapies for skin and soft tissue infections (SSTIs), a clinician discusses how providers can appropriately find the balance between these novel therapies, the existing treatment guidelines, and stewardship.

A clinician has a novel approach to patient conversations around this topic to determine if they want to assess if their penicillin allergies truly present a problem for treatment.

In episode 1 of this short video series, a clinician discusses what types of patients are best suited for inpatient or outpatient care for these infections.

Two patients at a hospital in Australia were administered Thin Film Freezing Voriconazole Inhalation Powder (TFF VORI), which showed treatment efficacy for both patients.

The investigational shot from Pfizer and Valneva demonstrated higher antibody levels in the three-dose vaccination schedule versus the two-dose vaccination schedule.

The World Health Organization (WHO) made the announcement today.

A clinician offers his perspective on what he sees as a clinician and trial investigator in terms of what is in the pipeline and both the encouraging data and uncertainty in therapy development overall.

One clinician discusses strategies in how his institution minimizes the wide spectrum approach to antibiotics as well as tries to prevent potential complications.

An ICU hospitalist talks about his criteria and the treatment protocols for these cases.

Safety profile in this study showed the frequency of adverse reactions with these boosters were similar or lower than that of either a second or third dose of the original vaccine.

Dynavax reported results from its phase 1 study looking at its (Tdap-1018 CpG Adjuvanted) Tetanus/Diphtheria/Pertussis booster vaccine.

In episode 1 of this short video series, a clinician discusses his experience in what his institution is seeing as well as how they handle their treatment protocol and stewardship where possible.

16 people have been reported to be infected across 6 states resulting in one death and a pregnancy loss in an expecting mother who became infected.

Frontier Biotechnologies reported data from its phase 1 trial for its investigational therapy, FB2001, for patients exposed to the virus.

In communities of color, hesitancy, mistrust, and access issues all drove low COVID-19 vaccination rates during the pandemic.

Vaccine efficacy of 81.8% was observed against severe medically attended lower respiratory tract illness due to respiratory syncytial virus (RSV) in infants from birth through the first 90 days of life.

Northwestern Medicine developed a testing strategy using a two-step algorithm to improve diagnostic accuracy and treatment outcomes.

One HIV clinical care program in Delaware looked into strategies to increase immunization rates to decrease severe disease as well as minimize hospital capacity.

The federal agency cited concerns regarding the manufacture and delivery of the therapy designed for adults with hepatitis delta virus (HDV).

Entasis presented follow-up data for its therapy, sulbactam-durlobactam (SUL-DUR), and its phase 3 ATTACK trial. The company is looking at a potential mid-2023 regulatory approval.